IL6 and COVID-19: We collected and included the patient population from August to September 2021 in our data analysis to observe the preliminary results on the effect of dexamethasone + remdesivir + tocilizumab treatment, as the use of tocilizumab (IL-6 inhibitor) was not granted emergency use authorization (EUA) for COVID-19 treatment in patients under supplemental oxygen or ventilation until June 24, 2021 [37].